ERSP on CigArrest
This article was originally published in The Tan Sheet
Executive Summary
CigArrest, marketer of the eponymous smoking cessation program, has adequately supported its general performance and safety claims, but should modify or discontinue its claim that users can "become a non-smoker in as little as seven days," according to an Electronic Retailing Self-Regulation Program decision Feb. 24. ERSP reviewed a TV ad and website promoting the product and expressed concern about claims such as: "clinically proven methods to help you avoid smoking in any situation" and "the most successful stop smoking program." However, the National Advertising Review Council division found that ingredient claims such as "the active ingredients work...by relieving nervous tension, irritability and the craving associated with withdrawal" were given "adequate" support by scientific literature. Additionally, safety claims including "all-natural, non-addictive" and "we have not had any serious reactions or adverse side-effects ever reported" were reasonably supported by the marketer, ERSP states. CigArrest is a homeopathic formula that includes Nux Vomica (poison nut) and Plantago Major (plantain), the marketer states...
You may also be interested in...
ERSP Review Of Claims Lights Fire Under Smoking-Cessation Marketer
Final Smoke Inc. voluntarily modifies claims for its smoking-cessation system, including a dietary supplement and homeopathic detoxification liquid, in conjunction with an Electronic Retailing Self-Regulation Program review
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.